NAS:NTRA (USA)
Business Description
Natera Inc
NAICS : 621511
SIC : 8071
13011 McCallen Pass, Building A Suite 100, Austin, TX, USA, 78753
Description
Natera Inc is operative in the healthcare field in the United States. Its core business is to offer invasive and other means of diagnosing the genetic features of a fetus. Natera's array of diagnostic services includes Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by studying the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother's blood and a blood sample from the alleged father. The Company acquires its revenue by billing an insurance carrier, a clinic, or a patient for the test upon delivery of the test result.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.59 | |||||
Equity-to-Asset | 0.42 | |||||
Debt-to-Equity | 0.91 | |||||
Debt-to-EBITDA | -0.73 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 2.61 | |||||
Beneish M-Score | -2.07 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 15.7 | |||||
3-Year EBITDA Growth Rate | -39.1 | |||||
3-Year EPS without NRI Growth Rate | -32.9 | |||||
3-Year FCF Growth Rate | -47.8 | |||||
3-Year Book Growth Rate | 136.7 | |||||
Future 3-5Y Total Revenue Growth Rate Industry Rank | 23.62 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 72.15 | |||||
9-Day RSI | 71.5 | |||||
14-Day RSI | 69.22 | |||||
6-1 Month Momentum % | -44.74 | |||||
12-1 Month Momentum % | -62.34 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.58 | |||||
Quick Ratio | 3.46 | |||||
Cash Ratio | 2.54 | |||||
Days Inventory | 26.13 | |||||
Days Sales Outstanding | 71.52 | |||||
Days Payable | 19.19 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.3 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 46.38 | |||||
Operating Margin % | -78.8 | |||||
Net Margin % | -79.56 | |||||
ROE % | -106.65 | |||||
ROA % | -51.3 | |||||
ROIC % | -217.23 | |||||
ROC (Joel Greenblatt) % | -357.06 | |||||
ROCE % | -62.81 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 7.24 | |||||
PB Ratio | 12.02 | |||||
Price-to-Tangible-Book | 12.02 | |||||
EV-to-EBIT | -9.02 | |||||
EV-to-Forward-EBIT | -9.26 | |||||
EV-to-EBITDA | -9.25 | |||||
EV-to-Revenue | 7.07 | |||||
EV-to-Forward-Revenue | 6.27 | |||||
EV-to-FCF | -10.57 | |||||
Price-to-Net-Current-Asset-Value | 19.16 | |||||
Price-to-Net-Cash | 324.53 | |||||
Earnings Yield (Greenblatt) % | -11.09 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:NTRA
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 723.477 | ||
EPS (TTM) ($) | -6.07 | ||
Beta | 1.48 | ||
Volatility % | 61.5 | ||
14-Day RSI | 69.22 | ||
14-Day ATR ($) | 3.333533 | ||
20-Day SMA ($) | 48.697 | ||
12-1 Month Momentum % | -62.34 | ||
52-Week Range ($) | 26.1 - 129.09 | ||
Shares Outstanding (Mil) | 96.96 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Natera Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |